Ascentage Pharma Group International - American Depository Shares

Predictability is restrained by clinical, regulatory, and payer milestones. Reported 2024 revenue (134.3 million dollars) was boosted by a one‑time Takeda option, then normalized in 2025 (82.1 million dollars) with healthy China product growth but continued operating losses.

The revenue base today is concentrated in one country and two products, and future step‑ups depend on registrational readouts and approvals across nine Phase 3 programs. Until ex‑China approvals and broader reimbursement for lisaftoclax are achieved, variability remains high.